United States · 
What does Aisling Capital invest in?
Aisling Capital invests most often at Venture and Series D (43% of the rounds on record), in sectors such as Health, Connected-health and E-health.
Aisling Capital highlights
- 01
1 cheques in the last 12 months
- 02
Mostly Venture and Series D: 43% of its rounds
- 03
4 exits from the portfolio
What they do
Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Up to $5.0M as they say
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- HealthConnected-healthE-health
- Based in
- New York, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first55 appearances
- 2026
1 round
- Oct
- 2019
1 round
- Oct
- 2015
5 rounds
- Jul
- Apr
- Mar
- Mar
- Feb
- 2014
7 rounds
- Oct
- Oct
- Aug
- Jun
- Jun
- May
- Feb
- 2013
10 rounds
- Dec
- Oct
- Oct
- Oct
- Jul
- Jul
- May
- Apr
- Mar
- Jan
- 2012
8 rounds
- Nov
- Oct
- Oct
- Jul
- Mar
- Mar
- Feb
- Jan
- 2011
5 rounds
- Sept
- Aug
- Feb
- Feb
- Jan
- 2010
4 rounds
- Sept
- Aug
- Jun
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration4 named
ANAndrew Newman SchiffCo-PresidentiForm ADV
DJDennis Joseph PurcellPresidentiForm ADV
RJRobert John WenzelChief Compliance Officer / Chief Financial OfficeriForm ADV
SASteven Arnote ElmsCo-PresidentiForm ADV
We also hold 18 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$780Massets it manages, 2 advisers combinedOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Aisling Capital LLC
- SEC number
- CRD 157698
Funds on its Form ADV
2 private funds, $511M in gross assets · filed Mar 2024
- Aisling Capital IV, L.P.Private equity24 investors$317M
- Aisling Capital V, L.P.Private equity39 investors$193M
What they claim to have backed
From their own portfolio page (on their website)
54 of 60 we have independently watched raise
AdmabiologicsAgiletherapeuticsAjaxhealthAntiostherapeuticsArcusbioArmobioAscendispharmaAtrecaAvrobioBiohavenpharmaBiomeafusionBridgebioCalcimedicaCempraCidaraClovisoncologyColorescienceCompasspathwaysDermiraDrenbioDuratatherapeuticsEarlensElevationoncologyF2gForgebiologicsGeneGondolabioHarmonybiosciencesJnjLensarLombardmedicalLoxooncologyMeipharmaMenlotherapeuticsNuvationbioObsevaPellepharmPoseidaProtagonist-incQuintilesReneopharmaScholarrockSkinmedicaSmithersavanzaSorrentotherapeuticsSprucebiosciencesT2biosystemsTreelineTriabeautyVeronapharmaVersartisViewrayViractaZosanopharmaActavisAdvionAegleabioAimmuneAllerganAmbitbioand 47 more
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed4 in all
LensARBought by ALPHAEON Corporation$59MNov 2015
Ambit BiosciencesBought by Daiichi Sankyo$410MSept 2014
Aragon PharmaceuticalsBought by Johnson & Johnson$1.0BJun 2013
NextWave PharmaceuticalsBought by PfizerUndisclosedOct 2012
An exit counts when it came after the firm's first round in the company. From historical deal records.